


DCISionRT®



Know Your Risk™
Before You Make a Decision

What is DCIS?

Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in one or both breasts. DCIS is considered the earliest form of breast cancer and is sometimes referred to as Stage 0 (zero). DCIS is noninvasive, meaning it has not spread out from the milk duct and has a lower risk of progressing to invasive breast cancer.




What is DCISionRT®?

DCISionRT is a risk assessment test for women diagnosed with DCIS. DCISionRT evaluates a patient's individual biology along with other risk factors to provide a personalized risk assessment. It predicts the risk of a future DCIS or invasive breast cancer recurrence in that same breast over the next 10 years. It also predicts the benefit from radiation therapy in reducing the risk of DCIS or invasive disease recurring.

Why would my physician use DCISionRT?

Your physician is gathering all of the available information to customize a treatment plan for you. Previously, most patients with a diagnosis of DCIS had typically been treated with surgery, radiation therapy and hormonal therapy. Today, DCISionRT provides additional information about your biological risk for the disease coming back and your likelihood of benefiting from radiation therapy. With this added information, your physician can recommend the best course of therapy for you, and together you can make a shared decision for treatment.




DCISionRT empowers women with information about their biological risk profile. Before you make a decision, Know Your Risk™.

How does DCISionRT work?


DCISionRT looks at the biology of your DCIS tissue and assesses seven different biomarkers along the key biologic pathways responsible for the progression of breast cancer as well as four other risk factors. The test can be performed on the biopsy or the tissue removed during surgery. No additional procedures are required.

We test your DCIS with **7** genes, their interactions, and their relationship to **4** factors about you.




When should I have the DCISionRT test?

The DCISionRT test may be performed before or after breast conserving surgery. The tissue removed during surgery requires no additional procedure. Most patients have the test after surgery, but this depends on your physician's preference and the goal of the treatment.




What information does DCISionRT provide?

The result of the test is called your DCISionRT Score. The Score is reported numerically on a scale from 0.0 to 10.0, and categorically as “Low” or “Elevated.”



The risk algorithm has been validated with information from thousands of patients with known outcomes and is used to calculate your individualized DCISionRT Score. Your DCISionRT Score correlates with your personal prognosis after treatment with surgery alone or with surgery and radiation therapy.




What do DCISionRT results mean to me and my doctor?

Your DCISionRT Score can be an important part of your doctor’s effort to evaluate your specific health needs and recommend the most appropriate treatment for your DCIS. Based upon your personalized results, the test allows you and your physician to make a shared decision whether surgery alone or surgery with radiation is appropriate.


Low Risk Example

This patient has a DCISionRT Score of 0.8 and is classified as having a low risk of recurrence. Total Risk (either invasive or DCIS) is 5% with surgery alone or 5% with surgery plus radiation. Ten-year risk of invasive breast cancer is 3% with surgery alone or surgery plus radiation. Prognosis is similar with breast conserving surgery alone or surgery plus radiation therapy.



Elevated Risk Example

A patient’s DCISionRT Score is 7.4 and is classified as having Elevated Risk of recurrence. Total Risk (either invasive or DCIS) is 29% with surgery alone or 10 year Invasive Risk is 19%. However, with surgery plus radiation, Total Risk is reduced to 5% and Invasive Risk is reduced to 3% -- a prognosis similar to low risk patient above.



What is “Total Risk” on the DCISionRT test report?

“Total Risk” is chance of having either DCIS or invasive breast cancer within the breast originally diagnosed over a period of 10 years.

What is “Invasive Risk” on the DCISionRT test report?

“Invasive Risk” indicates the chance of having invasive breast cancer in the breast originally diagnosed with DCIS over 10 years and does not include the risk of DCIS coming back.

What can I expect during the testing process?

DCISionRT is easily ordered by your breast care doctor. An order request can simply be faxed by your doctor's office to PreludeDx. Our Care Team then acquires your biopsy or surgical specimen from the hospital. Test results will be sent directly to your ordering physician's office. No additional biopsy or surgery is required.

When will I receive my DCISionRT test results?

We understand the anxiety associated with uncertainty and strive to deliver your results quickly so that you and your doctor can make informed decisions. PreludeDx is leading the way with unsurpassed turnaround time and provides results in as few as 3-5 days from receiving your DCIS tissue sample.



Will my insurance cover DCISionRT?

We believe that all eligible patients should have access to the DCISionRT test regardless of their insurance coverage or financial status. PreludeDx currently accepts all insurance plans and offers a variety of financial assistance programs.

The Billing Process

- When your physician orders DCISionRT, your insurance information is provided to us.
- We will contact the pathology department to obtain your specimen for testing.
- After the test is performed by our laboratory, results are delivered securely to your physician.
- We will bill your insurance company directly and assist in the appeals process. This process may take several months. Our Patient Care Team is available to discuss the process with you.
- You may need to sign a Designation of Authorized Representative form, which allows us to appeal to insurance companies on your behalf.
- Throughout this process, you may receive one or more Explanation of Benefits (EOB) statements from your insurance company – **an EOB is not a bill.**

Insurance companies usually will pay PreludeDx directly. In the event the insurance company issues payment to you, please forward the payment to us.



Patient Responsibility

Each patient's insurance coverage is unique, and the out-of-pocket amount varies based on deductible amounts (including what portion has been met), co-pay or co-insurance amounts of your particular health plan.

We will work on your behalf to ensure that the insurance company has processed the claim at the highest possible benefit level to minimize out-of-pocket expense.

If a payment is required after the insurance company has determined your benefit amount and your responsibility balance, we will issue an invoice for any outstanding deductible, co-pay or co-insurance amount. PreludeDx is sensitive to all patient needs and offers a variety of financial assistance programs.

Financial Assistance Programs

We never want the cost of the DCISionRT test to prohibit you and your physician from having the information you need to make an informed treatment decision. If you have any financial hardship associated with the patient responsibility amount, please contact our Patient Care Team.

Financial support programs are in place for:

- Uninsured Assistance
- Under-Insured Assistance
- Payment Plans
- Indigent Patient Assistance


**For more information
about these programs
call 888.211.3247**



**“My body and my choice
were given back to me
because of DCISionRT.”**

-Jennie D.

DCISionRT®



Your Biology, Your Decision
Know Your Risk™

To better understand our offering
and to speak to an expert
please visit **www.preludedx.com**
or call **888.211.3247**

Our commitment to you:

At PreludeDx, we realize that every sample we receive in our laboratory has a patient behind it. It is our mission to ensure we handle each sample with care. PreludeDx exists to serve the healthcare needs of our patients and physicians and to facilitate the shared decision-making process for better patient care.



26051 Merit Circle, Suite 103 | Laguna Hills, CA | 92653
T: 888.211.3247 | info@PreludeDx.com | PreludeDx.com